RE: RE: RE: RE: RE: RE: RE: RE: RE: RE: RE: shareh Firstly it seems currently to be the way that big pharma pays as little as possible up front and future royalties upon success. I understand that, just good business. I think that Don has already inferred this is his expectation when he commented something along the lines of the upfront payment would not be as high as some people expect.
I'm not sure it would even be a case of spend away. To me more like a way to get a greater piece of the big pie on the cheap.
My cynical side has definitely been twitching here given what I said in my previous posts especially when considering timing that could be interpretted as being designed to keep institutional holders out. One of the best ways of winning a battle is by keeping those that really can fight out of the fight in the first place.
I'm not saying this is the case, it could be the regular ill-conceived communication, but it definitely should be watched in my mind.